What is the role of verquvo in heart failure management?

What Verquvo Does in Heart Failure

Verquvo (vericiguat) is a soluble guanylate cyclase (sGC) stimulator approved for reducing cardiovascular death and heart failure hospitalization risk in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). It targets patients already on standard therapies like ACE inhibitors, ARBs, beta-blockers, or mineralocorticoid receptor antagonists who have worsened despite treatment.[1]

How Verquvo Fits into HFrEF Treatment Guidelines

Guidelines from the American College of Cardiology and American Heart Association recommend Verquvo as an add-on therapy for HFrEF patients (NYHA class II-IV) with recent hospitalization or need for IV diuretics. It slots in after foundational drugs in the "quadruple therapy" pillar (ARNI/ACEI/ARB + beta-blocker + MRA + SGLT2 inhibitor), particularly for those at high risk of events.[2][3] It's not first-line but helps when ejection fraction stays below 45% and symptoms persist.

Evidence from Key Clinical Trials

The VICTORIA trial, a phase 3 study of 5,050 HFrEF patients, showed Verquvo (started at 2.5 mg, titrated to 10 mg daily) cut the composite endpoint of CV death or HF hospitalization by 10% versus placebo (HR 0.90; 95% CI 0.82-0.98; p=0.02). Benefits held across subgroups, including those on sacubitril/valsartan.[4] No significant mortality benefit alone, but hospitalization reduction drove results. Common side effects included hypotension (9%) and anemia (7%), leading to 7.4% discontinuation rate.

Who Qualifies and When to Start It

Eligible patients have chronic HFrEF (EF ≤45%), elevated natriuretic peptides (NT-proBNP ≥600 pg/mL or BNP ≥150 pg/mL), and a recent HF event. Start after optimizing GDMT; monitor blood pressure (systolic <100 mmHg may require dose hold) and hemoglobin. Not for HFpEF or de novo cases without prior worsening.[1][2]

Dosing, Cost, and Access Issues

Take 2.5 mg or 5 mg orally once daily with food, titrating to 10 mg over 4-8 weeks based on tolerance. Monthly cost runs $600-700 without insurance; patient assistance programs from Merck cover copays for eligible U.S. patients.[5] Generic unavailable; Merck holds U.S. patent until at least 2033.[6]

How It Stacks Up Against Entresto or SGLT2 Inhibitors

Unlike Entresto (sacubitril/valsartan), which inhibits neprilysin to boost natriuretic peptides, Verquvo directly stimulates sGC to enhance nitric oxide signaling and vasodilation in failing hearts. It complements Entresto without interaction issues. Compared to SGLT2 inhibitors like dapagliflozin (which cut HF events by 25-30% via metabolic/osmotic effects), Verquvo shows smaller absolute risk reduction (4-5%) but targets a narrower high-risk group. Trials allow combination use.4

Patient Concerns: Side Effects and Monitoring

Hypotension affects 10%, often mild and transient; anemia from increased heme catabolism hits 5-7%, usually not severe. Syncope risk rises slightly. Regular BP checks and labs recommended. No black-box warnings, but avoid in pregnancy (Category not assigned; potential fetal harm).[1]

[1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213805s000lbl.pdf
[2]: https://www.jacc.org/doi/10.1016/j.jacc.2022.02.003
[3]: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063
[4]: https://www.nejm.org/doi/full/10.1056/NEJMoa1915928
[5]: https://www.merckhelps.com/verquvo
[6]: https://www.drugpatentwatch.com/p/tradename/VERQUVO